NCT06575595View on ClinicalTrials.gov

Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Healthy
Interventions
BIOLOGICAL

Tulisokibart

single dose via SC autoinjector (Treatment A) or concentration A or concentration B SC injection via syringe and vial (Treatments B and C)

Trial Locations (1)

65802

QPS Missouri ( Site 0003), Springfield

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06575595 - Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010) | Biotech Hunter | Biotech Hunter